Case Study: Pre-commercial access globally

A small US biotech company had an ultra-orphan medicine in development. The phase III trials were completed, and once approved, the medicine would be the first approved treatment for this ultra-rare disease.

The company was focused on obtaining approval and commercial launch in the US, but received high demand from patient advocacy groups for access to the medicine outside the US, where commercial availability would take longer.

Read the case study to discover how Clinigen enabled the company to provide pre-commercial access to 400 patients across Europe.